Opinion|Videos|January 26, 2026
Dose Modification Strategies With Triplet Therapies in AML
Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, discuss potential dose modification approaches for the use of triplet therapy in AML.
Advertisement
Episodes in this series
Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, address practical dose modification strategies when administering triplet therapies in acute myeloid leukemia (AML). They discuss how clinicians can adjust dosing to manage cytopenias, infectious risk, and cumulative toxicity while preserving efficacy. DiNardo and Altman highlight the importance of experience, monitoring, and flexibility when implementing complex combination regimens.
Advertisement
Related to this article
A prespecified analysis showed benefit with anselamimab in patients with kappa light chain AL amyloidosis.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The selective BCR::ABL1 inhibitor ELVN-001 produced major molecular responses in previously treated chronic-phase CML, including after asciminib progression.
Actinomycin D plus low-dose cytarabine and venetoclax produced high remission rates in a retrospective cohort of patients with NPM1-mutated AML.
Revumenib added to intensive chemotherapy produced deep, MRD-negative remissions with a manageable safety profile in newly diagnosed AML.
Ofirnoflast produced hematologic improvement in two-thirds of patients with ESA-refractory lower-risk MDS.
Mayo Clinic researchers identified a potential new approach to treating glioblastoma to improve the effectiveness of existing chemotherapy.
In the phase 2 RESTORE-PV trial, DISC-3405 cut phlebotomy events and maintained hematocrit below 45% in patients with polycythemia vera.
Advertisement
Advertisement
Trending on OncLive
1
Ofirnoflast Elicits Durable Transfusion Independence, Hematologic Improvement in Lower-Risk MDS
2
ACTIVE Regimen Elicits High Response Rates in R/R NPM1-Mutated AML
3
Revumenib Plus Chemo Yields High Response and MRD-Negativity Rates in Newly Diagnosed NPM1+ or KMT2A+ AML
4
Dr Gangat on Phase 2 Efficacy and Safety Data for DISC-3405 in Polycythemia Vera
5